Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lipoprotein(a) Should Be Measured in All Individuals Suspected of Having Familial Hypercholesterolemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. In Reply

    Research output: Contribution to journalLetterResearch

  4. Low HDL Cholesterol and High Risk of Autoimmune Disease: Two Population-Based Cohort Studies Including 117341 Individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.
Original languageEnglish
JournalClinical Chemistry (Washington, DC)
Volume56
Issue number10
Pages (from-to)1636-40
Number of pages5
ISSN0009-9147
DOIs
Publication statusPublished - 1 Oct 2010

ID: 32222949